Gadgeel's Preview of Key ESMO 2024 Findings in Lung Cancer - Targeted Oncology

September 13, 2024

Dr. Shirish M. Gadgeel discusses MARIPOSA-2 data at ESMO 2024, highlighting improvements in targeted therapies, immunotherapy combinations, and antibody-drug conjugates, emphasizing the ongoing trend of individualized cancer treatment for better efficacy and quality-of-life.

Related Clinical Trials

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Reference News

targetedonc.com

Gadgeel's Preview of Key ESMO 2024 Findings in Lung Cancer - Targeted Oncology